Aytu BioPharma, Inc. (AYTU) Q3 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Aytu Biopharma, Inc..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.000 -- 00:00:02.400 Please note this conference is being recorded. 00:00:02.400 -- 00:00:06.120 I will now turn the conference over to your host, Robert Bloom, Investor Relations at 00:00:06.120 -- 00:00:09.840 A2. Robert, you may begin. 00:00:09.840 -- 00:00:12.280 Thank you very much and good afternoon, everyone. 00:00:12.280 -- 00:00:17.320 As the operator indicated during today's call, we will be discussing A2 Biopharma's 00:00:17.320 -- 00:00:22.360 fiscal 2025 third quarter operational and financial results for the 00:00:22.360 -- 00:00:26.560 period ended March 31, 2025. 00:00:26.560 -- 00:00:31.580 With us on today's call is A2's Chief Executive Officer, Josh Dizbro, and 00:00:31.580 -- 00:00:35.380 Ryan Selhorn, the company's Chief Financial Officer. 00:00:35.380 -- 00:00:39.420 At the conclusion of today's prepared remarks, we'll open the call for a question and 00:00:39.420 -- 00:00:43.960 answer session. I'd like to remind everyone that today's call is being recorded. 00:00:43.960 -- 00:00:48.900 A replay of today's call will be available by using the teleconference numbers and conference 00:00:48.900 -- 00:00:53.960 ID provided in the press release issued earlier today, or by utilizing the 00:00:53.960 -- 00:00:58.700 link on the company's website under events and presentations. 00:00:58.700 -- 00:01:02.920 Finally, I'd also like to call to your attention the customary safe hardware disclosure 00:01:02.920 -- 00:01:07.280 regarding forward-looking information. The conference call today will contain certain 00:01:07.280 -- 00:01:11.940 forward-looking statements, including statements regarding the goals, strategies, beliefs, 00:01:11.940 -- 00:01:16.340 expectations, and future potential operating results of A2 Biopharma. 00:01:16.340 -- 0...